Skip to main content
. 2020 Nov 26;21(23):8984. doi: 10.3390/ijms21238984

Figure 5.

Figure 5

Cutaneous melanoma patients benefit from immune checkpoint blockade therapy better than non-cutaneous melanoma patients. Created with BioRender.com.